RU2383542C2 - Замещенные гидантоины - Google Patents

Замещенные гидантоины Download PDF

Info

Publication number
RU2383542C2
RU2383542C2 RU2007109651/04A RU2007109651A RU2383542C2 RU 2383542 C2 RU2383542 C2 RU 2383542C2 RU 2007109651/04 A RU2007109651/04 A RU 2007109651/04A RU 2007109651 A RU2007109651 A RU 2007109651A RU 2383542 C2 RU2383542 C2 RU 2383542C2
Authority
RU
Russia
Prior art keywords
dioxoimidazolidin
phenyl
lower alkyl
propionylthiazol
phenylbutyramide
Prior art date
Application number
RU2007109651/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2007109651A (ru
Inventor
Синьцзи ЧУ (US)
Синьцзи Чу
Надер ФОТУИ (US)
Надер ФОТУИ
Николас Джон Силвестер ХЬЮБИ (US)
Николас Джон Силвестер ХЬЮБИ
Норман КОНГ (US)
Норман КОНГ
Ли Апостле МАКДЕРМОТТ (US)
Ли Апостле МАКДЕРМОТТ
Джон Антони МОЛИТЕРНИ (US)
Джон Антони Молитерни
Джумин ДЖАН (US)
Джумин ДЖАН
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU2007109651A publication Critical patent/RU2007109651A/ru
Application granted granted Critical
Publication of RU2383542C2 publication Critical patent/RU2383542C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
RU2007109651/04A 2004-08-17 2005-08-09 Замещенные гидантоины RU2383542C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60217504P 2004-08-17 2004-08-17
US60/602,175 2004-08-17
US68299705P 2005-05-20 2005-05-20
US60/682,997 2005-05-20

Publications (2)

Publication Number Publication Date
RU2007109651A RU2007109651A (ru) 2008-09-27
RU2383542C2 true RU2383542C2 (ru) 2010-03-10

Family

ID=35589619

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007109651/04A RU2383542C2 (ru) 2004-08-17 2005-08-09 Замещенные гидантоины

Country Status (16)

Country Link
US (1) US7427635B2 (https=)
EP (1) EP1781649B1 (https=)
JP (1) JP4927733B2 (https=)
KR (2) KR20090006885A (https=)
AR (1) AR050297A1 (https=)
AT (1) ATE404556T1 (https=)
AU (1) AU2005274390B2 (https=)
BR (1) BRPI0514515A (https=)
CA (1) CA2576599A1 (https=)
DE (1) DE602005008986D1 (https=)
ES (1) ES2313389T3 (https=)
MX (1) MX2007001846A (https=)
PL (1) PL1781649T3 (https=)
RU (1) RU2383542C2 (https=)
TW (1) TW200621764A (https=)
WO (1) WO2006018188A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
CN101702878B (zh) * 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 可溶性差的药物的药物组合物
MX2010001581A (es) 2007-08-16 2010-03-15 Hoffmann La Roche Hidantoinas substituidas.
US8063085B2 (en) 2007-12-20 2011-11-22 Hoffmann-La Roche Inc. Substituted hydantoins
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
AU2009330686B2 (en) * 2008-06-16 2014-07-03 The Ohio State University Research Foundation Compounds for the treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011000945A2 (en) * 2009-07-03 2011-01-06 Nensius Research A/S Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns
EP3028699B1 (en) 2010-02-25 2018-03-21 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
MX2012010115A (es) 2010-03-01 2013-02-26 Gtx Inc Compuestos para el tratamiento de cancer.
CN103038364A (zh) 2010-03-09 2013-04-10 达纳-法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
BR112012027762B1 (pt) 2010-04-28 2018-06-05 Bayer Intellectual Property Gmbh Derivados de cetoheteroarilpiperidina e - piperazina como fungicidas
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
US12110299B2 (en) * 2018-09-17 2024-10-08 Yungjin Pharm. Co., Ltd. Thiazole derivatives and pharmaceutically acceptable salts thereof
WO2021182914A1 (ko) * 2020-03-13 2021-09-16 영진약품 주식회사 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염
US20230095520A1 (en) * 2020-03-13 2023-03-30 Yungjin Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating cancer comprising azole derivatives or pharmaceutically acceptable salt thereof
KR20210146144A (ko) 2020-05-26 2021-12-03 엘지전자 주식회사 카트부

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
WO2001083478A2 (en) * 2000-05-03 2001-11-08 F. Hoffmann-La Roche Ag Hydantoin-containing glucokinase activators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ501276A (en) 1997-07-01 2000-10-27 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
ATE345341T1 (de) * 2001-07-19 2006-12-15 Pfizer Italia Srl Phenylacetamido-thiazole verbindungen, verfahren zu ihren herstellung und ihre anwendung als antitumor mittel

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
WO2001083478A2 (en) * 2000-05-03 2001-11-08 F. Hoffmann-La Roche Ag Hydantoin-containing glucokinase activators

Also Published As

Publication number Publication date
AU2005274390B2 (en) 2012-01-19
WO2006018188A3 (en) 2006-05-18
ES2313389T3 (es) 2009-03-01
PL1781649T3 (pl) 2009-01-30
TW200621764A (en) 2006-07-01
CA2576599A1 (en) 2006-02-23
KR20090006885A (ko) 2009-01-15
KR20070034635A (ko) 2007-03-28
DE602005008986D1 (de) 2008-09-25
WO2006018188A2 (en) 2006-02-23
BRPI0514515A (pt) 2008-06-10
MX2007001846A (es) 2007-03-28
KR100889721B1 (ko) 2009-03-23
JP4927733B2 (ja) 2012-05-09
US20060041146A1 (en) 2006-02-23
ATE404556T1 (de) 2008-08-15
US7427635B2 (en) 2008-09-23
EP1781649B1 (en) 2008-08-13
AU2005274390A1 (en) 2006-02-23
EP1781649A2 (en) 2007-05-09
JP2008509950A (ja) 2008-04-03
AR050297A1 (es) 2006-10-11
RU2007109651A (ru) 2008-09-27

Similar Documents

Publication Publication Date Title
RU2383542C2 (ru) Замещенные гидантоины
RU2320648C2 (ru) 4,6,7,13-замещенные производные 1-бензил-изохинолина и фармацевтическая композиция, обладающая ингибирующей активностью в отношении гфат
JP2010531345A5 (https=)
RU97108980A (ru) Производные бензимидазола, антигистаминовая фармацевтическая композиция и способ лечения аллергических заболеваний
RU2001130163A (ru) Производные пиперидина и фармацевтическая композиция на их основе
HRP20141048T1 (hr) Spojevi, pripravci i metode
RU2004104625A (ru) Аналоги простагландинов в качестве агонистов рецептора ep4
JP2007519619A5 (https=)
JP2007519754A5 (https=)
RU2005117964A (ru) Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar
RU2007116317A (ru) Гексафторизопропанол-замещенные производные простых эфиров
WO2001074775A1 (fr) Derives d'indolin-2-one et leur utilisation en tant que ligands des recepteurs de l'ocytocine
RU99122343A (ru) Производные 2-(иминометил)аминофенила, способ их получения, их применение в качестве лекарственных средств и фармацевтические композиции на их основе
ZA200108739B (en) Renin inhibitors.
RU2006100190A (ru) Производные хинолиламида в качестве антагонистов ccr-5
RU2000131184A (ru) Соединения, обладающие свойствами, способствующими выделению гормона роста
RU2009148507A (ru) Производное тетрагидроизохинолин-1-она или его соль
JP2004529145A5 (https=)
JP2005532331A5 (https=)
RU2004133670A (ru) Способ лечения диабета
JP2008509950A5 (https=)
RU2007103304A (ru) Новые производные гексафторизопропанола
RU2007128082A (ru) Новые производные циклогексана
RU2015117578A (ru) Кетоамидные ингибиторы иммунопротеасом
JP2006512321A5 (https=)

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20130810